Stocks and Investing Stocks and Investing
Thu, November 9, 2023

Evan Seigerman Maintained (BIIB) at Buy with Decreased Target to $295 on, Nov 9th, 2023


Published on 2024-10-28 07:28:06 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of BMO Capital, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $314 to $295 on, Nov 9th, 2023.

Evan has made no other calls on BIIB in the last 4 months.



There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 2 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $275 on, Tuesday, August 8th, 2023
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $294 on, Tuesday, August 8th, 2023


These are the ratings of the 9 analyists that currently disagree with Evan


  • Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $305 on, Thursday, October 26th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $361 on, Wednesday, October 11th, 2023
  • Morten Herholdt of "HSBC" Initiated at Strong Buy and Held Target at $360 on, Wednesday, September 6th, 2023
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $335 on, Monday, August 14th, 2023
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $340 on, Tuesday, August 8th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $290 on, Monday, August 7th, 2023
  • George Farmer of "Scotiabank" Initiated at Buy and Held Target at $327 on, Thursday, July 27th, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Wednesday, July 26th, 2023
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $320 on, Tuesday, July 25th, 2023
Contributing Sources